NCT02182479View on ClinicalTrials.gov

Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

631

Participants

Timeline

Start Date

April 30, 1998

Primary Completion Date

June 30, 1999

Conditions
Asthma
Interventions
DRUG

Berodual® via Respimat®, high dose

DRUG

Berodual® via Respimat®, low dose

DRUG

Berodual® via MDI, high dose

DRUG

Placebo Respimat®

DRUG

Placebo MDI

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02182479 - Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients | Biotech Hunter | Biotech Hunter